608 related articles for article (PubMed ID: 15016654)
21.
Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
[TBL] [Abstract][Full Text] [Related]
22. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
[TBL] [Abstract][Full Text] [Related]
24. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction.
Marcenaro E; Cantoni C; Pesce S; Prato C; Pende D; Agaugué S; Moretta L; Moretta A
Blood; 2009 Nov; 114(19):4108-16. PubMed ID: 19749090
[TBL] [Abstract][Full Text] [Related]
25. Determinants of antileukemia effects of allogeneic NK cells.
Leung W; Iyengar R; Turner V; Lang P; Bader P; Conn P; Niethammer D; Handgretinger R
J Immunol; 2004 Jan; 172(1):644-50. PubMed ID: 14688377
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals.
Grau R; Lang KS; Wernet D; Lang P; Niethammer D; Pusch CM; Handgretinger R
Exp Mol Pathol; 2004 Apr; 76(2):90-8. PubMed ID: 15010286
[TBL] [Abstract][Full Text] [Related]
27. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
28. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
29. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
30. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch.
Vampa ML; Norman PJ; Burnapp L; Vaughan RW; Sacks SH; Wong W
Transplantation; 2003 Oct; 76(8):1220-8. PubMed ID: 14578757
[TBL] [Abstract][Full Text] [Related]
31. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Casucci M; Volpi I; Tosti A; Perruccio K; Urbani E; Negrin RS; Martelli MF; Velardi A
Blood; 1999 Jul; 94(1):333-9. PubMed ID: 10381530
[TBL] [Abstract][Full Text] [Related]
32. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
[TBL] [Abstract][Full Text] [Related]
33. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
[TBL] [Abstract][Full Text] [Related]
34. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
35. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
[TBL] [Abstract][Full Text] [Related]
36. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
37. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?
Rouas-Freiss N; Marchal RE; Kirszenbaum M; Dausset J; Carosella ED
Proc Natl Acad Sci U S A; 1997 May; 94(10):5249-54. PubMed ID: 9144223
[TBL] [Abstract][Full Text] [Related]
38. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.
Besser MJ; Shoham T; Harari-Steinberg O; Zabari N; Ortenberg R; Yakirevitch A; Nagler A; Loewenthal R; Schachter J; Markel G
PLoS One; 2013; 8(3):e57922. PubMed ID: 23483943
[TBL] [Abstract][Full Text] [Related]
39. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
40. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vĕtvicka V; Hanikýrová M; Vĕtvicková J; Ross GD
Clin Exp Immunol; 1999 Feb; 115(2):229-35. PubMed ID: 9933447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]